Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal immune and microbiome profiling during immunotherapy for solid tumors
NL-OMON55886Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ipilimumab and nivolumab in Nonhematologic neoplasms, sponsored by Leiden University Medical Center. Primary endpoints: Effect of immune-modulating therapies on systemic and local immunity, Additional immune-related biomarker profiling and 5 more. Started Jul 2018; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON55886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55886.